INSULET CORPORATION (PODD) Announces Clinical Trial Update
INSULET CORPORATION (PODD) provided an update on its clinical development programs.
Clinical Development Highlights:
Drug Program: distributed, tear
Collaboration: cost•All
🔬 Clinical Development Pipeline (INSULET CORPORATION):
Product
Type
Development Stage
Therapeutic Area
Source
Omnipod M system
DEVICE
Approved
Diabetes Mellitus
ClinicalTrials.gov
Multiple daily injections of insulin
DRUG
Approved
Type 1 Diabetes
ClinicalTrials.gov
Omnipod 5
DEVICE
Approved
Type 1 Diabetes
ClinicalTrials.gov
Active Comparator: Omnipod M System with higher starting dose
DEVICE
Approved
Type 2 Diabetes Mellitus
ClinicalTrials.gov
Active Comparator: Omnipod M System with lower starting dose
📋 INSULET CORPORATION (PODD) - Clinical Trial Update
Filing Date: 2026-03-12
Accepted: 2026-03-12 16:06:56
Event Type: Clinical Trial Update
Event Details:
🔬 Clinical Development Pipeline (INSULET CORPORATION):
💼 Business Developments:
No business developments data available.
Structured Data: